Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Outstanding (Weighted Average) (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $42.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 37.8% to $42.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.2 million through Dec 2025, up 37.8% year-over-year, with the annual reading at $30.9 million for FY2025, 59.53% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $42.2 million in Q4 2025 for Vistagen Therapeutics, up from $9.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $86.1 million in Q1 2021 to a low of $2.4 million in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $18.3 million across 5 years, with a median of $9.3 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 92.34% in 2022 and later skyrocketed 1125.73% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $6.7 million in 2021, then crashed by 64.45% to $2.4 million in 2022, then surged by 1125.73% to $29.4 million in 2023, then increased by 4.29% to $30.6 million in 2024, then soared by 37.8% to $42.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for VTGN at $42.2 million in Q4 2025, $9.3 million in Q3 2025, and $9.3 million in Q2 2025.